Ticker brief
ORKA ORUKA THERAPEUTICS INC
Consumer, Non-cyclical · Biotechnology
last close
$85.21
1 day
-8.7%
14 days
+17.8%
mkt cap
$5.1B
signals 14d
18
authors 14d
11
Sentiment — last 14 days
daily mean sentiment, 2026-06-19 → 2026-07-02 · now -0.20 (−1 bearish … +1 bullish)
Who spoke11
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @bioinvestor24 | A | +1.35 | 3 | +0.02 |
| @Quantumup1 | C | -1.95 | 3 | +0.35 |
| @SteveDJacobs | C | -0.20 | 3 | +0.20 |
| @Brad_E_Schulz | C | · | 2 | +0.35 |
| @dagoonglove | B | +0.71 | 1 | +0.60 |
| @PersimmonTI | A | -0.32 | 1 | +0.45 |
| @SpartanTrading | C | -1.69 | 1 | +0.10 |
| @HedgeFundTips | B | -0.75 | 1 | +0.00 |
| @SuperDuperInvst | C | -2.32 | 1 | +0.10 |
| @fj_nextstage | C | +1.07 | 1 | +0.05 |
| @CEOStockWatcher | C | · | 1 | -0.20 |
Recent signals18of 18 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-07-02 | @CEOStockWatcher | -0.20 | Fairmount Funds sold $300M of Oruka and reduced listed holdings by 48%. | — | tweet ↗ |
| 2026-07-01 | @Quantumup1 | +0.60 | UBS raises ORKA PT to 130 from 100 and reiterates Buy with bullish H2 data thesis. | -8.7% | tweet ↗ |
| 2026-06-28 | @SteveDJacobs | +0.20 | Screener lists 13 stocks passing both Qullamaggie and Minervini inspired screens. | -5.9% | tweet ↗ |
| 2026-06-27 | @SteveDJacobs | +0.20 | Minervini Trend Template screener lists 54 qualifying stocks. | -5.9% | tweet ↗ |
| 2026-06-27 | @SteveDJacobs | +0.20 | Qullamaggie-inspired screener lists 58 stocks, including 39 non-extended names. | -5.9% | tweet ↗ |
| 2026-06-26 | @fj_nextstage | +0.05 | Breakout and pivot watch list with IBD market exposure unchanged at 60-80%. | -5.9% | tweet ↗ |
| 2026-06-26 | @Quantumup1 | +0.00 | B Riley raised KYMR PT to $155 and reiterated Buy after enrollment update. | -5.9% | tweet ↗ |
| 2026-06-23 | @Quantumup1 | +0.45 | H.C. Wainwright reiterates Oruka Buy $120 commenting on APGE/ABBV deal parallels. | +2.2% | tweet ↗ |
| 2026-06-22 | @Brad_E_Schulz | +0.35 | Sector performance snapshot led by Bio/Pharm and lists strongest names. | -0.2% | tweet ↗ |
| 2026-06-22 | @SuperDuperInvst | +0.10 | Compares ORKA rally to VNDA and says VNDA should be far higher on valuation. | -0.2% | tweet ↗ |
| 2026-06-22 | @Brad_E_Schulz | +0.35 | Intraday category overview shows Bio/Pharm leading with many stocks up. | -0.2% | tweet ↗ |
| 2026-06-22 | @HedgeFundTips | +0.00 | Money flow screener list without explicit direction or analysis. | -0.2% | tweet ↗ |
| 2026-06-22 | @SpartanTrading | +0.10 | Premarket tickers on watch without trade intent. | -0.2% | tweet ↗ |
| 2026-06-22 | @PersimmonTI | +0.45 | Says it could be a good day to own ORKA/SYRE and implies APGE may have peaked. | -0.2% | tweet ↗ |
| 2026-06-22 | @dagoonglove | +0.60 | Bullish biotech thesis on ORKA psoriasis drug convenience, data, and potential M&A appeal. | -0.2% | tweet ↗ |
| 2026-06-19 | @bioinvestor24 | +0.25 | Says ORKA has its IL23 antibody and good assets. | +17.8% | tweet ↗ |
| 2026-06-19 | @bioinvestor24 | +0.00 | Calls IL17 a dying business and criticizes MRK interest in MLTX versus IL23/IL13 opportunities. | +17.8% | tweet ↗ |
| 2026-06-19 | @bioinvestor24 | -0.20 | Author says SYRE has much better assets than ORKA. | +17.8% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.